Collectively, after all these filtering steps we identified 11 FDA-approved drugs that target 4 of the 28 MM gene products (EDNRB, HGF, CCL3, ADM) and have not yet undergone evaluation in MM patients (Table 2). This evidence concerns the gene ADM and Miyoshi myopathy.